CITIUS ONCOLOGY, INC.

Citius Oncology, Inc., trading under the ticker TENK, is the resulting entity from TenX Keane Acquisition Corp.'s de-SPAC transaction in the healthcare and oncology sector. TenX Keane Acquisition, sponsored by TenX Keane Capital Management LLC, completed its initial public offering in 2021 and targeted opportunities in the life sciences and biopharmaceutical space. The October 2023 8-K filing marks a material corporate event tied to the business combination that brought Citius Oncology — spun out of Citius Pharmaceuticals — into the public markets under the TENK ticker. The combined company focuses on oncology therapeutics development. Sign up on SpacDesk for full filing history, sponsor profiles, and real-time deal tracking on TENK and hundreds of other SPACs.